ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

Stock Information for ChromaDex Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ChromaDex Corporation

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
ChromaDex to Present at Canaccord Genuity's 44th Annual Growth Conference
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.